Literature DB >> 20033389

[Scleroderma].

O Distler1, S Gay.   

Abstract

Scleroderma (synonyms: systemic sclerosis, systemic scleroderma) is a systemic disease which affects the skin as well as internal organs such as the lungs, gastrointestinal tract, kidneys, and the heart. Pathogenetically a distinction should be made between uncontrolled formation of extracellular matrix proteins (fibrosis) and vasculopathy. In addition to organ fibrosis, this leads to a clinical picture of vascular manifestations. These include fingertip ulcers, pulmonary arterial hypertension, and acute renal crisis. Localized forms of scleroderma, such as morphea, which do not involve organ complications, should be differentiated from systemic sclerosis. Due to its clinical heterogeneity and high rate of morbidity and mortality, systemic sclerosis poses an enormous diagnostic and therapeutic challenge in everyday clinical practice. This review article summarizes the current status of classification and epidemiology, pathogenesis, and the most important clinical manifestations such as interstitial fibrosis, pulmonary arterial hypertension, acute renal crisis, and peripheral vasculopathy and provides an overview of current and future treatment options.

Entities:  

Mesh:

Year:  2010        PMID: 20033389     DOI: 10.1007/s00108-009-2405-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

Authors:  Silvia Svegliati Baroni; Mariarosaria Santillo; Federica Bevilacqua; Michele Luchetti; Tatiana Spadoni; Matteo Mancini; Paolo Fraticelli; Paola Sambo; Ada Funaro; Andrius Kazlauskas; Enrico V Avvedimento; Armando Gabrielli
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

Review 2.  The controversial role of tumor necrosis factor alpha in fibrotic diseases.

Authors:  Jörg H W Distler; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2008-08

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

4.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

5.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Ursula Schulze-Horsel; Jochen Zwerina; Renate E Gay; Beat A Michel; Thomas Hauser; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2007-01

6.  Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.

Authors:  C Sunderkötter; I Herrgott; C Brückner; P Moinzadeh; C Pfeiffer; J Gerss; N Hunzelmann; M Böhm; T Krieg; U Müller-Ladner; E Genth; E Schulze-Lohoff; M Meurer; I Melchers; G Riemekasten
Journal:  Br J Dermatol       Date:  2009-01-13       Impact factor: 9.302

Review 7.  Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.

Authors:  S Guiducci; O Distler; J H W Distler; M Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

8.  Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.

Authors:  S I Nihtyanova; G M Brough; C M Black; C P Denton
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

9.  Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis.

Authors:  Mirko Manetti; Elena Neumann; Adelheid Müller; Tim Schmeiser; Petra Saar; Anna Franca Milia; Esther Endlicher; Elke Roeb; Luca Messerini; Marco Matucci-Cerinic; Lidia Ibba-Manneschi; Ulf Müller-Ladner
Journal:  Arthritis Rheum       Date:  2008-09

Review 10.  Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis.

Authors:  Christian Beyer; Georg Schett; Steffen Gay; Oliver Distler; Jörg H W Distler
Journal:  Arthritis Res Ther       Date:  2009-04-21       Impact factor: 5.156

View more
  2 in total

Review 1.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

2.  Molecular targets for therapy in systemic sclerosis.

Authors:  Naoki Iwamoto; Oliver Distler
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.